# A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]

> **NCT02367794** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 1021 (actual)

## Conditions studied

- Squamous Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody
- **DRUG:** Carboplatin
- **DRUG:** Nab-Paclitaxel
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT02367794
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-11
- **Primary completion:** 2018-10-03
- **Final completion:** 2021-02-17
- **Target enrollment:** 1021 (ACTUAL)
- **Last updated:** 2022-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02367794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02367794, "A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02367794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*